Back
Status filter :


RESET SEARCH AND FILTERS
Skin
Skin / Gustatory sweating
  propantheline bromide Hospital only
Skin / Hyperhidrosis
  aluminium chloride hexahydrate Joint formulary choice
  Liquid
Anhydrol (Dermal Laboratories Ltd) Joint formulary choice
  botulinum toxin type A Hospital only NICE TA260
NICE TA605
  Powder for solution for injection
Azzalure (Galderma (UK) Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
Bocouture (Merz Pharma UK Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
Botox (AbbVie Ltd) Hospital only
Dysport (Ipsen Ltd) Hospital only
Xeomin (Merz Pharma UK Ltd) Hospital only
  glycopyrronium bromide Non-formulary at HHFT and not suitable for primary care prescribing
Skin / Scalp and hair conditions
  benzalkonium chloride Not approved for prescribing
  Shampoo
Dermax (Dermal Laboratories Ltd) Not approved for prescribing
  cetrimide with undecenoic acid Not approved for prescribing
  coal tar Joint formulary choice
  Shampoo
Coal tar (Non-proprietary) Joint formulary choice
Neutrogena T/Gel Therapeutic (Johnson & Johnson Ltd) Joint formulary choice
Polytar Scalp (Thornton & Ross Ltd) Joint formulary choice
  Cutaneous emulsion
Exorex (Teva UK Ltd) Joint formulary choice
  coal tar with salicylic acid and precipitated sulfur Joint formulary choice
  ketoconazole Joint formulary choice
  Shampoo
Ketoconazole (Non-proprietary) Joint formulary choice
Dandrazol (Transdermal Ltd) Joint formulary choice
Nizoral (Thornton & Ross Ltd) Joint formulary choice
  selenium Joint formulary choice
Skin / Alopecia
  finasteride Not approved for prescribing
  minoxidil Not approved for prescribing
  Liquid
Minoxidil (Non-proprietary) Not approved for prescribing
Regaine (Johnson & Johnson Ltd, McNeil Products Ltd) Not approved for prescribing
Skin / Hirsutism
  co-cyprindiol Joint formulary choice
  eflornithine Not approved for prescribing
Skin / Superficial soft-tissue injuries and superficial thrombophlebitis
  heparinoid Not approved for prescribing
Skin / Dry and scaling skin disorders
  barrier creams and ointments
  Cutaneous cream
Sudocrem (Teva UK Ltd) Joint formulary choice
  emollient bath and shower products, antimicrobial-containing Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

  Bath additive
Dermol 600 (Dermal Laboratories Ltd) Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

Emulsiderm (Dermal Laboratories Ltd) Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

Oilatum Plus (Thornton & Ross Ltd) Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

  emollient bath and shower products, paraffin-containing Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

  Bath additive
Emollient bath and shower products, paraffin-containing (Non-proprietary) Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

Dermalo (Dermal Laboratories Ltd) Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

Doublebase (Dermal Laboratories Ltd) Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

Zerolatum (Thornton & Ross Ltd) Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

  Form unstated
E45 emollient bath (Karo Pharma UK Ltd) Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

  Products without form
Emollient bath and shower products, paraffin-containing (Non-proprietary) Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

  Cutaneous wash
Emollient bath and shower products, paraffin-containing (Non-proprietary) Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

E45 emollient wash (Karo Pharma UK Ltd) Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

  emollient bath and shower products, soya-bean oil-containing Not approved for prescribing
Bath emollients are non-formulary unless recommended by a dermatologist in exceptional circumstances

Bath emollients are non-formulary and are not recommended by C&H CCG. An appropriate emollient (e.g. emulsifying ointment) should be used in warm bath water rather than a specific bath emollient product. Bath emollients can be prescribed in exceptional circumstances when this is recommended by a dermatologist for a child; a cost-effective choice should be made (e.g. not Aveeno® bath emollient).

  Bath additive
Zeroneum (Thornton & Ross Ltd) Not approved for prescribing
  emollient creams and ointments, antimicrobial-containing Joint formulary choice
  emollient creams and ointments, colloidal oatmeal-containing Joint formulary choice
  Form unstated
Emollient creams and ointments, colloidal oatmeal-containing (Non-proprietary) Joint formulary choice
  emollient creams and ointments, paraffin-containing Joint formulary choice
  Liquid
Emollient creams and ointments, paraffin-containing (Non-proprietary) Joint formulary choice
  Spray
Emollin (C D Medical Ltd) Joint formulary choice
  Products without form
Adex (Dermal Laboratories Ltd) Joint formulary choice
Joint Prescribing Group's decision

June 2019 - the JPG agreed to approved the addition of Adex® gel to the joint formulary for dry skin conditions associated with inflammation and redness that would benefit from a steroid-free emollient with an added anti-inflammatory effect.

  emollients, urea-containing Joint formulary choice
  Products without form
Emollients, urea-containing (Non-proprietary) Not approved for prescribing
Dermatonics Once (Dermatonics Ltd) Joint formulary choice
Flexitol (Thornton & Ross Ltd) Joint formulary choice
Skin / Acne
  adapalene Joint formulary choice
  adapalene with benzoyl peroxide Joint formulary choice
Joint Prescribing Group's decision

May 2019 - the JPG agreed to approved the addition of Epiduo® (adapalene and benzoyl peroxide gel) to the joint formulary for acne vulgaris. 

  azelaic acid Joint formulary choice
  benzoyl peroxide Joint formulary choice
  benzoyl peroxide with clindamycin Joint formulary choice
  clindamycin Joint formulary choice
  co-cyprindiol Joint formulary choice
  doxycycline Joint formulary choice
  Modified-release capsule
Efracea (Galderma (UK) Ltd) Joint formulary choice
  erythromycin with zinc acetate Joint formulary choice
  Liquid
Zineryt (Neon Healthcare Ltd) Joint formulary choice
  isotretinoin Hospital only
  lymecycline Joint formulary choice
  minocycline Not approved for prescribing
  Modified-release capsule
Acnamino MR (Dexcel-Pharma Ltd) Not approved for prescribing
Minocin MR (Viatris UK Healthcare Ltd) Not approved for prescribing
  nicotinamide Not approved for prescribing
  oxytetracycline Joint formulary choice
  tretinoin with clindamycin Joint formulary choice
  tretinoin with erythromycin Not approved for prescribing
  Liquid
Aknemycin Plus (Almirall Ltd) Not approved for prescribing
Skin / Rosacea
  azelaic acid Joint formulary choice
  brimonidine tartrate Not approved for prescribing
  ivermectin Joint formulary choice
Skin / Sun protection and photodamage
  fluorouracil Not approved for prescribing
  fluorouracil with salicylic acid Not approved for prescribing
  Cutaneous solution
Actikerall (Almirall Ltd) Not approved for prescribing
  ingenol mebutate Not approved for prescribing
  tirbanibulin Hospital only
North East London Formulary & Pathways Group’s Decision – Tirbanibulin ointment for treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis of the face or scalp in adults

November 2023 - The North East London Formulary & Pathways Group (FPG) approved tirbanibulin ointment for treatment of non-hyperkeratotic, non-hypertrophic (Olsen grade 1) actinic keratosis of the face or scalp in adults. This treatment should only be prescribed by a dermatology specialist as:

  • Co-first line in single or multiple lesions for transplant or immunocompromised patients. 
  • Second line for treatment failures/contra-indication to topical 5-fluorouracil in other patients.​ 

GPs could gain support via Advice & Guidance (A&G) and refer patients back to secondary care clinicians if discharged patients attended the practice with treatment concerns. 

 

  Cutaneous ointment
Klisyri (Almirall Ltd) Hospital only
Skin / Warts and calluses
  camellia sinensis Hospital only
  formaldehyde Not approved for prescribing
  Liquid
Formaldehyde (Non-proprietary) Not approved for prescribing
  imiquimod Joint formulary choice
  podophyllotoxin Joint formulary choice
  Liquid
Warticon (Phoenix Labs Ltd) Joint formulary choice
  salicylic acid Joint formulary choice
  Liquid
Occlusal (Alliance Pharmaceuticals Ltd) Joint formulary choice
  salicylic acid with lactic acid Joint formulary choice
  Cutaneous paint
Duofilm (Thornton & Ross Ltd) Joint formulary choice
Salactol (Dermal Laboratories Ltd) Not approved for prescribing
  silver nitrate Hospital only
Skin / Eczema and psoriasis
  abrocitinib Hospital only NICE TA814
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service

This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service.

  Oral tablet
Cibinqo (Pfizer Ltd) Hospital only
  acitretin Hospital only
  adalimumab Hospital only NICE TA187
NICE TA329
NICE TA199
NICE TA195
NICE TA375
NICE TA715
NICE TA383
NICE TA392
NICE TA146
NICE TA460
North East London Formulary & Pathways Group’s Decision - Adalimumab escalated dosing for psoriasis

October 2023 - The North East London Formulary & Pathways Group (FPG) approved the use of Adalimumab escalated dose for moderate to severe plaque psoriasis in adult patients who have inadequate reqponse to standard dosing.

Approved escalated maintenance dose: 40mg once weekly (or 80mg every 2 weeks if reduced frequency of dosing required).

Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Humira (AbbVie Ltd) Hospital only
ADALIMUMAB

Dose escalation of Adalimumab is approved for Crohn's disease and ulcerative colitis

  alclometasone dipropionate Not approved for prescribing
  alitretinoin Hospital only NICE TA177
  apremilast Hospital only NICE TA433
NICE TA419
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  azathioprine Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  baricitinib Hospital only NICE TA466
NICE TA681
NICE TA926
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  beclometasone dipropionate Not approved for prescribing
  betamethasone Joint formulary choice
North East London Formulary & Pathways Group's Decision

November 2022 - The North East London Formulary & Pathways Group (FPG) approved the use of Betesil® (Betamethasone valerate) 2.25mg medicated plasters. This is indicated for the treatment of inflammatory skin disorders which do not respond to treatment with less potent corticosteroids, such as eczema, lichenification, lichen planus, granuloma annulare, palmoplantar pustulosis and mycosis fungoides.

Formulary status: Amber (specialist knowledge/initiation) - to be initiated by or on recommendation of a dermatologist or GPwSI in dermatology.

  Liquid
Betacap (Dermal Laboratories Ltd) Joint formulary choice
Betnovate (GlaxoSmithKline UK Ltd) Joint formulary choice
Diprosone (Organon Pharma (UK) Ltd) Joint formulary choice
  Medicated plaster
Betesil (Derma UK Ltd) Specialist knowledge/initiation
North East London Formulary & Pathways Group's Decision

November 2022 - The North East London Formulary & Pathways Group (FPG) approved the use of Betesil® (Betamethasone valerate) 2.25mg medicated plasters. This is indicated for the treatment of inflammatory skin disorders which do not respond to treatment with less potent corticosteroids, such as eczema, lichenification, lichen planus, granuloma annulare, palmoplantar pustulosis and mycosis fungoides.

Formulary status: Amber (specialist knowledge/initiation) - to be initiated by or on recommendation of a dermatologist or GPwSI in dermatology.

  betamethasone with clioquinol Joint formulary choice
  betamethasone with clotrimazole Joint formulary choice
  betamethasone with fusidic acid Joint formulary choice
  betamethasone with neomycin Joint formulary choice
  betamethasone with salicylic acid Joint formulary choice
  Liquid
Diprosalic (Organon Pharma (UK) Ltd) Joint formulary choice
  bimekizumab Hospital only NICE TA723
NICE TA916
NICE TA918
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Bimzelx (UCB Pharma Ltd) Hospital only
  brodalumab Hospital only NICE TA511
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Kyntheum (LEO Pharma) Hospital only
  calcipotriol Joint formulary choice
  Liquid
Calcipotriol (Non-proprietary) Joint formulary choice
  calcipotriol with betamethasone Joint formulary choice
  calcitriol Joint formulary choice
  certolizumab pegol Hospital only NICE TA375
NICE TA383
NICE TA415
NICE TA445
NICE TA574
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Cimzia (UCB Pharma Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
  ciclosporin Shared care guideline NICE TA369
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  Oral solution
Neoral (Novartis Pharmaceuticals UK Ltd) Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

Sandimmun (Novartis Pharmaceuticals UK Ltd) Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  Solution for infusion
Sandimmun (Novartis Pharmaceuticals UK Ltd) Hospital only
  clobetasol propionate Joint formulary choice
  Liquid
Dermovate (GlaxoSmithKline UK Ltd) Joint formulary choice
  Shampoo
Etrivex (Galderma (UK) Ltd) Joint formulary choice
  clobetasol propionate with neomycin sulfate and nystatin Specialist knowledge/initiation
  clobetasone butyrate Joint formulary choice
  clobetasone butyrate with nystatin and oxytetracycline Joint formulary choice
  coal tar Joint formulary choice
  Cutaneous emulsion
Exorex (Teva UK Ltd) Joint formulary choice
  coal tar with calamine Not approved for prescribing
  coal tar with coconut oil and salicylic acid Joint formulary choice
  Shampoo
Capasal (Dermal Laboratories Ltd) Joint formulary choice
  coal tar with dithranol and salicylic acid Not approved for prescribing
  coal tar with salicylic acid Not approved for prescribing
  coal tar with salicylic acid and precipitated sulfur Joint formulary choice
  coal tar with zinc oxide Not approved for prescribing
  deucravacitinib Hospital only NICE TA907
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Oral tablet
Sotyktu (Bristol-Myers Squibb Pharmaceuticals Ltd) Hospital only
  dimethyl fumarate Hospital only
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

Skilarence® NICE TA475
Tecfidera® NICE TA320
  Gastro-resistant tablet
Skilarence (Almirall Ltd) Hospital only
  dithranol Specialist knowledge/initiation
  dithranol with salicylic acid and zinc oxide Not approved for prescribing
  dupilumab Hospital only NICE TA534
NICE TA751
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Dupixent (Sanofi) Hospital only
  etanercept Hospital only NICE TA103
NICE TA195
NICE TA375
NICE TA715
NICE TA199
NICE TA383
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

Biosimilar preparation is available for this

Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept

  Solution for injection
Benepali (Biogen Idec Ltd) Hospital only
Biosimilar preparation is available for this

Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept

Enbrel (Pfizer Ltd) Hospital only
Biosimilar preparation is available for this

Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept

Enbrel MyClic (Pfizer Ltd) Hospital only
Biosimilar preparation is available for this

Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept

Erelzi (Sandoz Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
Biosimilar preparation is available for this

Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept

  Powder and solvent for solution for injection
Enbrel (Pfizer Ltd) Hospital only
Biosimilar preparation is available for this

Benepali (etanercept biosimilar) is the formulary choice brand of Etanercept

  fludroxycortide Joint formulary choice
  Impregnated dressing
Fludroxycortide (Non-proprietary) Specialist knowledge/initiation
  fluocinolone acetonide Joint formulary choice NICE TA301
NICE TA613
NICE TA590
  fluocinonide Joint formulary choice
  fluticasone Not approved for prescribing
  guselkumab Hospital only NICE TA521
NICE TA815
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Tremfya (Janssen-Cilag Ltd) Hospital only
  hydrocortisone Joint formulary choice
  hydrocortisone butyrate Joint formulary choice
  Liquid
Locoid (Neon Healthcare Ltd) Joint formulary choice
  hydrocortisone with benzalkonium chloride, dimeticone and nystatin Joint formulary choice
  hydrocortisone with chlorhexidine hydrochloride and nystatin Not approved for prescribing
  hydrocortisone with clotrimazole Joint formulary choice
  hydrocortisone with fusidic acid Joint formulary choice
  hydrocortisone with miconazole Joint formulary choice
  hydrocortisone with oxytetracycline Not approved for prescribing
  ichthammol Not approved for prescribing
  ichthammol with zinc oxide Specialist knowledge/initiation
  Impregnated dressing
Ichthopaste (Evolan Pharma AB) Not approved for prescribing
  infliximab Hospital only NICE TA134
NICE TA195
NICE TA375
NICE TA715
NICE TA199
NICE TA187
NICE TA163
NICE TA329
NICE TA383
Biosimilar

Remsima® (biosimilar infliximab) is the formulary choice brand for infliximab.

Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Remsima (Celltrion Healthcare UK Ltd) Hospital only
  ixekizumab Hospital only NICE TA442
NICE TA537
NICE TA718
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Taltz (Eli Lilly and Company Ltd) Hospital only
  methotrexate Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  Oral solution
Methotrexate (Non-proprietary) Shared care guideline
A formal Shared Care Guideline (SCG) may be available

Happy to prescribe

If you are asked to continue treatment for a specific condition for which a shared care guideline is available and you are happy to prescribe in accordance with the guidance then take over the agreed responsibilities, including prescribing. Please obtain a copy of the SCG from secondary care or via the link below. 

Unhappy to prescribe

If sufficient information has not been provided and if you do not feel happy to continue to prescribe then it is advisable to refer the patient back to the specialist clinic. Please complete an inappropriate request communication form and send this as soon as possible to the contact provided in the form. 

  Solution for injection
Methotrexate (Non-proprietary) Hospital only
Metoject PEN (medac UK) Hospital only
Nordimet (Nordic Pharma Ltd) Hospital only
Zlatal (Nordic Pharma Ltd) Hospital only
  Solution for infusion
Methotrexate (Non-proprietary) Hospital only
  mometasone furoate Joint formulary choice
  Liquid
Elocon (Organon Pharma (UK) Ltd) Joint formulary choice
  pimecrolimus Joint formulary choice NICE TA82
  risankizumab Hospital only NICE TA596
NICE TA803
NICE TA888
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Skyrizi (AbbVie Ltd) Hospital only
  secukinumab Hospital only NICE TA350
NICE TA407
NICE TA719
NICE TA445
NICE TA935
Dose escalation of secukinumab for severe chronic plaque psoriasis

April 2023 - The North East London Formulary & Pathways Group approved use of Secukinumab at increased dosing freequency of 300mg every 2 weeks for patients with severe chronic plaque psoriasis who have secondary failure (as per NICE's description) with a body weight of 90kg or higher. Patients who have an inadequate response after 3 months of dose escalation should be offered alternative treatment as per the NEL High Cost Drug Psoriasis Pathway. 

Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Cosentyx (Novartis Pharmaceuticals UK Ltd) Hospital only
  tacalcitol Joint formulary choice
  tacrolimus Joint formulary choice NICE TA82
NICE TA481
NICE TA481
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Modified-release tablet
Envarsus (Chiesi Ltd) Not approved for prescribing
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Modified-release capsule
Advagraf (Astellas Pharma Ltd) Not approved for prescribing
Brand prescribing recommended

Although generic prescribing is encouraged, there are some circumstances in which it is preferable to prescribe by brand name, these include where:

  • there are differences in bioavailability between brands of the same medicine
  • modified-release (MR) preparations that are not interchangeable
  • administration devices have different instructions for use and patient familiarity with one product is important
  • there are important differences in formulation between brands of the same medicine
  • branded and generic preparations have different licensed indications
  • products contain more than one ingredient and brand-name prescribing aids identification.

Please prescribe this product by brand.

  Solution for infusion
Prograf (Astellas Pharma Ltd) Not approved for prescribing
  tildrakizumab Hospital only NICE TA575
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  tralokinumab Hospital only NICE TA814
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service

This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service.

  Solution for injection
Adtralza (LEO Pharma) Hospital only
  upadacitinib Hospital only NICE TA665
NICE TA744
NICE TA768
NICE TA829
NICE TA861
NICE TA814
NICE TA856
NICE TA905
  Modified-release tablet
Rinvoq (AbbVie Ltd) Hospital only
  ustekinumab Hospital only NICE TA180
NICE TA340
NICE TA456
NICE TA633
North East London Formulary & Pathways Group’s Decision – Ustekinumab dose escalation for moderate to severe psoriasis

June 2023 - The North East London Formulary & Pathways Group (FPG) approved dose escalation of ustekinumab for plaque psoriasis.

  • Patients ≤ 100 kg -Ustekinumab 45 mg SC every 12 weeks (licensed dose) may be increased to a maximum of 90 mg every 8 weeks  
  • Patients >100kg -Ustekinumab 90 mg every 12 weeks (licensed dose) may be increased to a maximum of 90 mg every 8 weeks 

For use in patients with a waning response to maintenance dose of ustekinumab before next scheduled dose as quantified by the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) after full discussion at MDT.  

Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Stelara (Janssen-Cilag Ltd) Hospital only
  Solution for infusion
Stelara (Janssen-Cilag Ltd) Hospital only
Skin / Urticaria
  acrivastine Not approved for prescribing
  alimemazine tartrate Not approved for prescribing
  Oral solution
Alimemazine tartrate (Non-proprietary) Not approved for prescribing
  desloratadine Not approved for prescribing
  Oral solution
Desloratadine (Non-proprietary) Not approved for prescribing
Neoclarityn (Organon Pharma (UK) Ltd) Not approved for prescribing
  fexofenadine hydrochloride Joint formulary choice
  levocetirizine hydrochloride Not approved for prescribing
  Oral solution
Xyzal (UCB Pharma Ltd) Not approved for prescribing
  loratadine Joint formulary choice
  Oral solution
Loratadine (Non-proprietary) Joint formulary choice
  Oral tablet
Loratadine (Non-proprietary) Joint formulary choice
  mizolastine Not approved for prescribing
  Modified-release tablet
Mizollen (Sanofi Consumer Healthcare) Not approved for prescribing
  omalizumab Hospital only NICE TA278
NICE TA339
Where positive NICE Technology Appraisal(s) apply to this medicine

This medicine is recommended for use at Homerton Healthcare NHS Foundation Trust provided it is used specifically in accordance with the relevant current NICE Technology Appraisal(s).

  Solution for injection
Xolair (Novartis Pharmaceuticals UK Ltd) Hospital only
  promethazine hydrochloride Joint formulary choice
  Oral solution
Phenergan (Sanofi Consumer Healthcare) Joint formulary choice
  rupatadine Not approved for prescribing
Skin / Skin cleansers, antiseptics and desloughing agents
  alcohol Not approved for prescribing
  Form unstated
Alcohol (Non-proprietary) Not approved for prescribing
  chlorhexidine Joint formulary choice
  Liquid
Cepton (Dendron Brands Ltd) Not approved for prescribing
Hibi (Molnlycke Health Care Ltd) Joint formulary choice
Hibiscrub (Molnlycke Health Care Ltd) Joint formulary choice
Hydrex (Ecolab Healthcare Division) Joint formulary choice
  chlorhexidine gluconate with isopropyl alcohol Joint formulary choice
  Liquid
ChloraPrep (Becton, Dickinson UK Ltd) Joint formulary choice
  chlorhexidine with cetrimide Not approved for prescribing
  diethyl phthalate with methyl salicylate Not approved for prescribing
  Liquid
Diethyl phthalate with methyl salicylate (Non-proprietary) Not approved for prescribing
  hydrogen peroxide Joint formulary choice
  Liquid
Hydrogen peroxide (Non-proprietary) Joint formulary choice
  Mouthwash
Peroxyl (Colgate-Palmolive (UK) Ltd) Not approved for prescribing
  potassium permanganate Joint formulary choice
  Tablet for cutaneous solution
Potassium permanganate (Non-proprietary) Joint formulary choice
Permitabs (Alliance Pharmaceuticals Ltd) Joint formulary choice
  povidone-iodine Joint formulary choice
  Liquid
Videne (Ecolab Healthcare Division) Joint formulary choice
  proflavine Not approved for prescribing
Skin / Minor cuts and abrasions
  castor oil with collodion and colophony Not approved for prescribing
  glycerol with magnesium sulfate and phenol Not approved for prescribing
Skin / Pruritus
  alimemazine tartrate Not approved for prescribing
  Oral solution
Alimemazine tartrate (Non-proprietary) Not approved for prescribing
  calamine with zinc oxide Not approved for prescribing
  Liquid
Calamine with zinc oxide (Non-proprietary) Not approved for prescribing
  cetirizine hydrochloride Joint formulary choice
  Oral solution
Cetirizine hydrochloride (Non-proprietary) Joint formulary choice
  Oral tablet
Cetirizine hydrochloride (Non-proprietary) Joint formulary choice
  chlorphenamine maleate Joint formulary choice
  Oral solution
Chlorphenamine maleate (Non-proprietary) Joint formulary choice
Allerief (Crescent Pharma Ltd) Joint formulary choice
Piriton (Haleon UK Ltd) Joint formulary choice
  Solution for injection
Chlorphenamine maleate (Non-proprietary) Hospital only
  Oral tablet
Chlorphenamine maleate (Non-proprietary) Joint formulary choice
  coal tar with calamine Not approved for prescribing
  crotamiton Joint formulary choice
  difelikefalin Non-formulary at HHFT and not suitable for primary care prescribing NICE TA890
Where positive NICE Technology Appraisal(s) apply to this medicine but Homerton Healthcare NHS Foundation Trust does not provide the service

This medicine is not recommended for use at Homerton Healthcare NHS Foundation Trust as the trust does not provide this specialist service. Note that this medicine may be prescribed by other provider trusts that are accredited to provide this specialist service.

  Solution for injection
Kapruvia (Vifor Fresenius Medical Care Renal Pharma UK Ltd) Non-formulary at HHFT and not suitable for primary care prescribing
  doxepin Not approved for prescribing
Doxepin cream not approved for vulvodynia

March 2022 - The JPG did not recommend the use of doxepin 5% cream for the treatment of vulvodynia due to the lack of safety and efficacy evidence to support use in this cohort of patients. 

  hydroxyzine hydrochloride Joint formulary choice
  levocetirizine hydrochloride Not approved for prescribing
  Oral solution
Xyzal (UCB Pharma Ltd) Not approved for prescribing
  levomenthol Not approved for prescribing
Skin / Bacterial skin infections
  metronidazole Joint formulary choice
  mupirocin Joint formulary choice
  Nasal ointment
Bactroban (GlaxoSmithKline UK Ltd) Joint formulary choice
  silver sulfadiazine Hospital only
Skin / Fungal skin infections
  amorolfine Joint formulary choice
  Medicated nail lacquer
Amorolfine (Non-proprietary) Joint formulary choice
Loceryl (Galderma (UK) Ltd) Not approved for prescribing
  benzoic acid with salicylic acid Not approved for prescribing
  chlorhexidine with nystatin Not approved for prescribing
  clotrimazole Joint formulary choice
  Liquid
Canesten (Bayer Plc) Joint formulary choice
  Spray
Canesten (Bayer Plc) Joint formulary choice
  Cutaneous cream
Clotrimazole (Non-proprietary) Joint formulary choice
  econazole nitrate Not approved for prescribing
  griseofulvin Joint formulary choice
  hydrocortisone with clotrimazole Joint formulary choice
  ketoconazole Joint formulary choice
  miconazole Joint formulary choice
  Spray
Daktarin (Johnson & Johnson Ltd) Joint formulary choice
  terbinafine Joint formulary choice
  Oral tablet
Terbinafine (Non-proprietary) Joint formulary choice
  Cutaneous cream
Terbinafine (Non-proprietary) Joint formulary choice
Lamisil (Haleon UK Ltd) Joint formulary choice
  tioconazole Not approved for prescribing
  undecenoic acid with zinc undecenoate Not approved for prescribing
Skin / Parasitic skin infections
  benzyl benzoate Not approved for prescribing
  dimeticone Joint formulary choice
  Liquid
Hedrin (Thornton & Ross Ltd) Joint formulary choice
Lyclear (Omega Pharma Ltd) Joint formulary choice
  Cutaneous spray solution
Hedrin (Thornton & Ross Ltd) Joint formulary choice
  ivermectin Not approved for prescribing
  malathion Joint formulary choice
  permethrin Joint formulary choice
  Liquid
Lyclear (Omega Pharma Ltd) Joint formulary choice
Skin / Viral skin infections
  aciclovir Joint formulary choice